Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

After falling 17 per cent since the start of the year to its March lows, the stock of the country’s largest pharmaceutical ...

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions ...

Leqselvi is a medicine used to treat severe alopecia areata, manufactured by Sun Pharmaceutical. The generic name of the drug ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning ...

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

Sun Pharma stock rose more than 5 per cent intraday on Friday, April 11, after the company got a favorable order from a US ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...